TTR and myocardial infarction: Second, the final diagnosis of ATTR-CA was not available for all suspicious patients; therefore, an underestimation/overestimation of the true prevalence of ATTR-CA cannot be excluded due to possible false negative (i.e., some transthyretin gene mutations) or false positive results (i.e., myocardial scar due to previous myocardial infarction or some cases of AL-CA) of bone scintigraphy, which should be taken into account in an unselected population in particular.